Hims & Hers Health Inc (HIMS) Quarterly Institutional 13F Update (Q2 2026)

HIMS ranks #1104 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

HIMS is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

530 institutions disclose a position in HIMS, but none treat it as a major bet — even Divisadero Street Capital Management, LP, its most concentrated holder, allocates just 4.7% of its own portfolio to it.

Marshall Wace, LLP has added to its HIMS position for two straight quarters, increasing it by $146.0M to reach $146.2M today.

Wellington Management Group LLP has trimmed its HIMS position for two straight quarters, cutting it by $25.7M while still holding $10.9M.

HIMS is up 2.6% today, and institutions have been net buyers of $1.2B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

HIMS reported a net loss of $142.0M over the trailing twelve months.

• Not yet profitable — net loss of $142.0M over the trailing twelve months
• Revenue grew 28.0% year over year
• Net income declined year over year, from $193.6M to -$142.0M
• Generated $300.0M in positive operating cash flow
• Current ratio of 1.90x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.98x equity — a highly leveraged balance sheet worth noting